Compare IMCR & TNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | TNC |
|---|---|---|
| Founded | 2008 | 1870 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.1B |
| IPO Year | 2016 | 1994 |
| Metric | IMCR | TNC |
|---|---|---|
| Price | $30.86 | $64.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $61.82 | ★ $91.00 |
| AVG Volume (30 Days) | ★ 348.6K | 282.9K |
| Earning Date | 05-15-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 1.93% |
| EPS Growth | ★ 30.39 | N/A |
| EPS | N/A | ★ 2.36 |
| Revenue | $249,428,000.00 | ★ $1,137,600,000.00 |
| Revenue This Year | $14.39 | $5.44 |
| Revenue Next Year | $8.19 | $5.28 |
| P/E Ratio | ★ N/A | $27.18 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $23.15 | $60.18 |
| 52 Week High | $40.71 | $85.91 |
| Indicator | IMCR | TNC |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 38.03 |
| Support Level | N/A | $60.18 |
| Resistance Level | $34.86 | $84.24 |
| Average True Range (ATR) | 1.51 | 1.96 |
| MACD | -0.19 | 0.25 |
| Stochastic Oscillator | 16.99 | 72.36 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.